Current place of beta-blockers in the treatment of hypertension

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 733-741

  Bielecka Dabrowa, A ^a   Aronow, Wilbert S ^b   Rysz, Jacek ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antihypertensive treatment; Beta blocker; Cardiovascular risk; Hypertension

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ATENOLOL; ATENOLOL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CAPTOPRIL; CARTEOLOL; CARVEDILOL; CELIPROLOL; ESMOLOL; HYDROCHLOROTHIAZIDE; LABETALOL; LACIDIPINE; LOSARTAN; METOPROLOL; NADOLOL; NEBIVOLOL; OXPRENOLOL; PERINDOPRIL; PINDOLOL; PLACEBO; PROPRANOLOL; SOTALOL; TIMOLOL; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HYPERTENSION; META ANALYSIS; MICROALBUMINURIA; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 77958112847     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563861     Document Type: Article

References (99)

1. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-17
2. Sarafidis PA, Lasaridis A, Gousopoulos S, et al. Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study. J Hum Hypertens 2004; 18: 623-669
3. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153: 598-615
4. MacMahon S, Rodgers A, Neal B, et al. Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension 1997; 29: 537-538
5. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187
6. Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag 2008; 4: 23-30
7. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993; 94: 181-187
8. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-921
9. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-745.
10. Frishman W, Silverman R. Clinical pharmacology of the new betaadrenergic blocking drugs. Part 2. Physiologic and metabolic effects. Am Heart J 1979; 97: 797-807
11. Garrett BN, Kaplan NM. Plasma renin activity suppression: duration after withdrawal from beta-adrenergic blockade. Arch Intern Med 1980; 140: 1316-1318
12. Pedersen ME, Cockcroft JR. The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep 2006; 8: 279-286
13. Opie L, Yusuf S. Beta-blocking agents. In: Opie LH, Gersh B, Eds. Drugs for the Heart. 6. Philadelphia, Pennsylvania: W.B. Saunders Company 2005; pp. 1-32
14. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-1362
15. Manrique C, Giles TD, Ferdinand KC, et al. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens 2009; 11: 369-375
16. Kaplan N. Systemic hypertension: therapy. In: Zipes D, Libby P, Bonow R, et al., Eds. Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. 7. Philadelphia, Pennsylvania: Elsevier Saunders 2005b; pp. 989-1012
17. Black HR, Sica DA. A modern perspective on beta-blocker use in hypertension: clinical trials and their influence on clinical practice. J Clin Hypertens (Greenwich) 2007; 9: 10-18
18. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-1689
19. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553
20. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians 2006
21. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536
22. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999; 318: 1730-1737
23. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001; 3: 351-357
24. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001; 38: 1581-1583.
25. Smith SC Jr, Allen J, Blair SN, et al. ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372.
26. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572
27. Mancia G. Prevention of risk factors: beta-blockade and hypertension. Eur Heart J 2009; 11 (Suppl A): A3-A8
28. Kowalski J, Banach M, Barylski M, Irzmanski R, Pawlicki L. Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett 2008; 13: 230-239
29. Houghton T, Freemantle N, Cleland JG. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail 2000; 2: 333-340.
30. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737-1742
31. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Betablockers for primary prevention of heart failure in patients with hypertension. Insights from a meta-analysis. J Am Coll Cardiol 2008; 52: 1062-1072
32. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol 1994; 74: 674-680
33. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol vs. no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients 62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction 40%. Am J Cardiol 1994; 74: 267-270
34. Aronow WS, Banach M. Atrial fibrillation: the new epidemic of the ageing world. J Atrial Fib 2009; 1: 337-361
35. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-207
36. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10
37. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100: 1254-1262
38. Zanchetti A, Hennig M, Baurecht H, et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intimamedia thickness. J Hypertens 2007; 25: 2463-2470
39. Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C. Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs 2006; 6: 209-217.
40. Bakris GL, Fonseca V, Katholi RF, et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension. a randomized controlled trial. JAMA 2004; 292: 2227-2236
41. Frishman WH. Carvedilol. N Engl J Med 1998; 339: 1759-1765
42. Cutler JA, Davis BR. Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation 2008; 117: 2691-2704
43. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-157
44. Mozaffarian D, Marfisi R, Levantesi G, et al. Incidence of newonset diabetes and impaired fasting glucose in patients with recent myocardial infarction andthe effect of clinical and lifestyle risk factors. Lancet 2007; 370: 667-675
45. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130-1134.
46. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003
47. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906
48. Devereux RB, de Faire U, Fyhrquist F, et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin 2007; 23: 259-270
49. Bang LE, Wiinberg N, Wachtell K, et al. Losartan vs. atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. Blood Press 2007; 16: 392-397
50. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Longterm follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576
51. Blackburn JL. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. J Hypertens 2007; 25:1499-1505
52. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816
53. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers vs. diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-572
54. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988; 259: 1976-1982
55. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151-158.
56. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? a systematic review. JAMA 1998; 279:1903-1907
57. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535
58. Dahlöf B, Devereux RB, Kjeldsen SE, Lyle PA, Zhang Z, Edelman JM. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? Blood Press 2007; 16: 6-12
59. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br Med J 2008; 336: 1121-1123
60. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: 1665-1683.
61. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185
62. Berenson A. Big drug makers see sales erode with their image. New York Times, Published online: November 14th, 2005. (http://query.nytimes.com/gst/fullpage.html?res=9D06E4DF103EF 937A25752C1A9639C8B63&sec=health)
63. Sarafidis PA, Bakris GL. Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens 2007; 25: 249-252
64. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for initial treatment of hypertension: II. Results of long-term therapy. JAMA 1982; 248: 2004-2011
65. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-123
66. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225
67. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-123
68. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor beyond blood pressure lowering, beyond blood pressure or beyond the brachial artery? J Hypertens 2005; 23: 551-556
69. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism(s) of selective blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92-99
70. Broeders MAW, Doevendans PA, Bekkers BCAM, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta2-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102: 677-684
71. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Thirdgeneration beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107: 2747-2752
72. Wikstrand J, Kendall M. The role of beta receptor blockade in preventing sudden death. Eur Heart J 1992; 12 (suppl D): 111-20.
73. Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120: 166-171
74. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993; 94: 181-187
75. Warmack TS, Estes MS, Heldenbrand s, Franks AM. ß-Adrenergic Antagonists in Hypertension: A Review of the Evidence. Ann Pharmacother 2009; 43: 2031-2043
76. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315
77. Weber MA, Neutel JM, Cheung DG. Hypertension in the aged: pathophysiologic basis for treatment. Am J Cardiol 1989; 63: 25H32H
78. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379-392
79. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27: 2121-2158
80. Goch A, Misiewicz P, Rysz J, Banach M. The clinical manifestation of myocardial infarction in elderly patients. Clin Cardiol 2009; 32: E46-51
81. Campbell NR, Khan NA, Hill MD, et al. 2009 Canadian Hypertension Education Program recommendations: the scientific summaryan annual update. Can J Cardiol 2009; 25: 271-277
82. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol vs. other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008; 1: 35-44
83. Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients with and without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006; 27: 562-568
84. Khoury AF, Sunderajan P, Kaplan NM. The early morning rise in blood pressure is related mainly to ambulation. Am J Hypertens 1992; 5: 339-344
85. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blockerinduced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008; 52: 1482-1489
86. Boutouyrie P, Bussy C, Hayoz D, et al. Local pulse pressure and regression of arterial wall hypertrophy during long term antihypertensive treatment. Circulation 2000; 101: 2601-2606
87. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-569
88. Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, D'Onofrio F. Effects of perindopril and carvedilol on endotheliumdependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998; 21: 631-636
89. Lopez BL, Christopher TA, Yue TL, Ruffolo R, Feuerstein GZ, Ma XL. Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 1995; 51: 165-173
90. Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005; 508: 159-166
91. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44: 305-10.
92. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26: 351-356
93. Gluba A, Banach M, Mikhailidis DP, Rysz J. Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. In Vivo 2009; 23: 797-812
94. Ramezani MA, Dastanpour M, Eshaghi SR, Fadaee-Nobari R, Heydari K. Determinants of awareness, treatment and control of hypertension in Isfahan, Central Iran. Arch Med Sci 2009; 5: 523-530
95. Goch A, Banach M, Mikhailidis DP, Rysz J, Goch JH. Endothelial dysfunction in patients with non-complicated and complicated hypertension. Clin Exp Hypertens 2009; 31: 20-30
96. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009; 5: 3-9
97. Refaat S, El-Ghaffar NA, Negm HAE-R, Yousri T. The role of aldosterone in myocardial dysfunction of Egyptian patients with essential hypertension. Arch Med Sci 2008; 4: 161-166
98. Desai RV, Banach M, Ahmed MI, et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010; 106: 221-227
99. Tatli E, Aktoz M, Gul C, Buyuklu M, Kurum T. Does carvedilol therapy reduce QT dispersion in patients with heart failure? Arch Med Sci 2008; 4: 404-408.